Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Non-Current Deffered Revenue: 2016-2024

Historic Non-Current Deffered Revenue for Rhythm Pharmaceuticals (RYTM) over the last 3 years, with Sep 2024 value amounting to $109.2 million.

  • Rhythm Pharmaceuticals' Non-Current Deffered Revenue rose 4.34% to $109.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $109.2 million, marking a year-over-year increase of 4.34%. This contributed to the annual value of $106.1 million for FY2023, which is 40.01% up from last year.
  • According to the latest figures from Q3 2024, Rhythm Pharmaceuticals' Non-Current Deffered Revenue is $109.2 million, which was up 0.80% from $108.4 million recorded in Q2 2024.
  • In the past 5 years, Rhythm Pharmaceuticals' Non-Current Deffered Revenue registered a high of $109.2 million during Q3 2024, and its lowest value of $3.0 million during Q1 2020.
  • Its 3-year average for Non-Current Deffered Revenue is $96.1 million, with a median of $105.4 million in 2023.
  • Data for Rhythm Pharmaceuticals' Non-Current Deffered Revenue shows a peak YoY skyrocketed of 40.01% (in 2023) over the last 5 years.
  • Rhythm Pharmaceuticals' Non-Current Deffered Revenue (Quarterly) stood at $3.0 million in 2020, then reached $75.8 million in 2022, then skyrocketed by 40.01% to $106.1 million in 2023, then climbed by 4.34% to $109.2 million in 2024.
  • Its Non-Current Deffered Revenue stands at $109.2 million for Q3 2024, versus $108.4 million for Q2 2024 and $107.4 million for Q1 2024.